Phase IV O2 Consumption study in COPD patients.

Trial Identifier: D589CC00014
Sponsor: AstraZeneca
NCTID:: NCT02533505
Start Date: August 2015
Primary Completion Date: August 2016
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, CT Hartford, CT, United States of America, 06105
United States of America, MA Boston, MA, United States of America, 02115
United States of America, NC Charlotte, NC, United States of America, 28207
United States of America, OH Cincinnati, OH, United States of America, 45267
United States of America, PA Philadelphia, PA, United States of America, 19140
United States of America, SC Spartanburg, SC, United States of America, 29303